TargetMol

CG0009

Product Code:
 
TAR-T30807
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30807-5mg5mg£930.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30807-50mg50mg£1,821.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30807-100mg100mg£2,319.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CG0009 is a potent and highly selective glycogen synthase kinase 3 (GSK3) inhibitor that inhibitions proliferation, induces apoptosis, and activates the p53-Bax pathway in breast cancer cells through cyclin D1 depletion. CG0009 inhibit breast cancer cell growth through cyclin D1 depletion and p53 activation, and thus may provide an innovative treatment approach for breast cancer resistant to hormone-based therapies.
CAS:
944744-57-4
Formula:
C26H31N7O
Molecular Weight:
457.582
Purity:
0.98
SMILES:
CCN(CC)CCN(C)c1ccc(cc1)-c1nc2c(ccnc2[nH]1)C(=O)Nc1cnccc1C

References

1. Cho, J.-M.; et. al. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same. WO2007083978A1. 2. Kim, H. M.; et. al. CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells. PLoS One 2013, 8(4), e60383.